CAMBRIDGE, Mass., Feb. 11, 2021 -- Codiak BioSciences, Inc. , a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today the pricing of its underwritten public offering of 2,750,000 shares of its common stock at a public offering price of $21.00 per share, for gross proceeds of approximately $57.8 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares are being offered by Codiak. In addition, Codiak has granted the underwriters a 30-day option to purchase up to an additional 412,500 shares of its common stock, at the public offering price, less underwriting discounts and commissions. All the shares to be sold in the proposed offering will be sold by Codiak.
The offering is expected to close on February 17, 2021, subject to customary closing conditions.
Goldman Sachs & Co. LLC, Evercore ISI and William Blair are acting as joint book-running managers for the offering and as representatives of the underwriters. Wedbush PacGrow is acting as lead manager for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission (“SEC”) and became effective on February 11, 2021. This offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, or by email: firstname.lastname@example.org; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, telephone: (888) 474-0200, or by email: email@example.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, telephone: 1-800-621-0687, or by email: firstname.lastname@example.org.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
高盛、Evercore ISI和William Blair将担任此次发行的联合账簿管理人和承销商代表。Wedbush PacGrow将担任此次发行的主要经理人。
与这些证券相关的注册声明已向美国证券交易委员会（“SEC”）备案，并于2021年2月11日生效。本次发售仅以招股章程方式进行。最终招股说明书的副本可以在SEC的网站上获得，网址是http://www.sec.gov，也可以联系高盛公司，联系电话:ProcessTus Department,200 West Street,New York,New York 10282，电话:1-866-471-2526，或者通过电子邮件:processTusemail@example.com；或Evercore Group L.L.C.,注意:Equity Capital Markets,55 East 52 Street,36 Floor,New York,NY 10055,电话:（888）474-0200，或通过电子邮件:ecm.prospectus@Evercore.com；或William Blair&Company,L.L.C.,地址:伊利诺伊州芝加哥北河滨广场150号招股说明书部,电话:1-800-621-0687,或通过电子邮件:Prospectus@williamblair.com。